Responses
Clinical and epidemiological research
Extended report
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
Compose a Response to This Article
Other responses
No responses have been published for this article.